Affordable Access

Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.

Authors
  • Kalb, Robert E
  • Gurske, Jennifer
Type
Published Article
Journal
Journal of the American Academy of Dermatology
Publisher
Elsevier
Publication Date
Oct 01, 2005
Volume
53
Issue
4
Pages
616–622
Identifiers
PMID: 16198781
Source
Medline
License
Unknown

Abstract

Infliximab was extremely effective and well tolerated in this group of patients with severe, recalcitrant psoriasis. Thirty-nine of 52 patients have continued receiving treatment for a median duration of 25 months with excellent disease control. Infliximab can provide control of extensive psoriasis with continued intermittent infusions.

Report this publication

Statistics

Seen <100 times